Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2059269 | 0.80 | CA1 (0.55) | CA12CA1CA2CA4CA7 | |
| SCHEMBL28956706 | 0.75 | ALDH1A1 (0.50) | ALDH1A1L3MBTL1 | |
| SCHEMBL9958753 | 0.74 | DDB1 (0.31) | — | |
| SCHEMBL2774997 | 0.74 | SLC6A2 (0.49) | CA12CA1CA2CA4CA7 | |
| SCHEMBL9557282 | 0.70 | MAPT (0.47) | ALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL9696629 | 0.69 | CA12 (0.30) | CA12CA1CA9 | |
| SCHEMBL1691876 | 0.69 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3POLBALDH1A1 | |
| SCHEMBL943601 | 0.67 | HPGD (0.47) | SLC6A2SLC6A4SLC6A3ALDH1A1HTT | |
| SCHEMBL942982 | 0.67 | MAPK1 (0.37) | ALDH1A1MAPK1L3MBTL1TSHR | |
| SCHEMBL1363113 | 0.67 | MAPT (0.50) | SLC6A2SLC6A4SLC6A3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8901184-B2 | Foamed resin molded article, foam insulated wire, cable and method of manufacturing foamed resin molded article | HITACHI METALS, LTD. (JP) | 2014-12-02 | — | — | US | disclosed |
| US-20140080933-A1 | FOAMED RESIN MOLDED ARTICLE, FOAM INSULATED WIRE, CABLE AND METHOD OF MANUFACTURING FOAMED RESIN MOLDED ARTICLE | HITACHI CABLE, LTD. (JP) | 2014-03-20 | — | — | US | disclosed |
| US-20050272936-A1 | Imidazolium cxcr3 inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-12-08 | — | — | US | disclosed |
| US-5869522-A | SOLVENT EXTRACTION; PLANT EXTRACTS; TRIMERIZATION OF 2,3-DEOXY-1,4-NAPHTHOQUINONE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-02-09 | — | — | US | disclosed |
| US-5783598-A | Antiretroviral naphthoquinone compounds compositions and uses thereof | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SEVICES (US) | 1998-07-21 | — | — | US | disclosed |
| US-5672607-A | FOR TREATING OR PREVENTING VIRAL OR RETROVIRAL INFECTIONS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-09-30 | — | — | US | disclosed |
| EP-0681578-B1 | ANTIVIRAL NAPHTHOQUINONE COMPOUNDS, COMPOSITIONS AND USES THEREOF | US HEALTH (US) | 1997-05-07 | — | — | EP | disclosed |
| EP-0681578-A1 | ANTIVIRAL NAPHTHOQUINONE COMPOUNDS, COMPOSITIONS AND USES THEREOF. | US HEALTH (US) | 1995-11-15 | — | — | EP | disclosed |
| WO-1994017055-A1 | ANTIVIRAL NAPHTHOQUINONE COMPOUNDS, COMPOSITIONS AND USES THEREOF | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1994-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272936-A1 | Imidazolium cxcr3 inhibitors | CXCR3, CXCR1, CCR7 | CA12 2359/4885CA1 2015/4885CA2 976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.